About Merus Labs International (NASDAQ:MSLI)
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Generic Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:MSLI
- CUSIP: N/A
- Web: www.meruslabs.com/
- 50 Day Moving Avg: $1.20
- 200 Day Moving Avg: $0.94
- 52 Week Range: $0.70 - $1.33
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 32.50
- P/E Growth: 0.00
- Net Margins: -5.18%
- Return on Equity: -2.51%
- Return on Assets: -1.32%
- Debt-to-Equity Ratio: 0.50%
- Current Ratio: 0.80%
- Quick Ratio: 0.54%
- Average Volume: 93,359 shs.
- Beta: 1.56
Frequently Asked Questions for Merus Labs International (NASDAQ:MSLI)
What is Merus Labs International's stock symbol?
Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."
How were Merus Labs International's earnings last quarter?
Merus Labs International Inc (NASDAQ:MSLI) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.03. The company earned $7.73 million during the quarter, compared to analysts' expectations of $17.19 million. Merus Labs International had a negative return on equity of 2.51% and a negative net margin of 5.18%. View Merus Labs International's Earnings History.
Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?
6 brokers have issued 1-year price targets for Merus Labs International's shares. Their predictions range from $1.00 to $1.65. On average, they anticipate Merus Labs International's share price to reach $1.35 in the next twelve months. View Analyst Ratings for Merus Labs International.
Who are some of Merus Labs International's key competitors?
Some companies that are related to Merus Labs International include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Smith & Nephew plc (SNN), Hospira (HSP), Waters (WAT), Smith & Nephew plc (SN), Omnicare (OCR), Ionis Pharmaceuticals (IONS), VCA (WOOF), NMC Health PLC (NMC), Catalent (CTLT), Valeant Pharmaceuticals Intl (VRX), Health Net (HNT), Galapagos NV (GLPG), Patheon NV (PTHN) and Mediclinic International PLC (MDC).
Who are Merus Labs International's key executives?
Merus Labs International's management team includes the folowing people:
- Michael S. Cloutier, Independent Chairman of the Board
- Barry Fishman, Chief Executive Officer, Director
- Michael Scott Bumby, Chief Financial Officer
- Robert McLay, Vice President - Sales and Marketing
- Frank Rotmann, Vice President and Head of European Operations
- Robert Bloch M.D., Director
- Theresa Sheila Firestone, Independent Director
- David D. Guebert CPA, Independent Director
- Robert S. Pollock, Independent Director
- Timothy G. Sorensen, Independent Director
How do I buy Merus Labs International stock?
Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus Labs International's stock price today?
MarketBeat Community Rating for Merus Labs International (NASDAQ MSLI)MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Merus Labs International stock can currently be purchased for approximately $1.30.
Earnings History for Merus Labs International (NASDAQ:MSLI)Earnings History by Quarter for Merus Labs International (NASDAQ MSLI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/14/2017||Q117||($0.02)||($0.04)||$23.18 million||$19.53 million||View||Listen|
|8/10/2015||Q3 2015||$0.02||($0.01)||$17.19 million||$7.73 million||View||N/A|
Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
2017 EPS Consensus Estimate: ($0.01)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Merus Labs International (NASDAQ:MSLI)
Latest Headlines for Merus Labs International (NASDAQ:MSLI)
Merus Labs International (MSLI) Chart for Saturday, October, 21, 2017